Product Description
Mechanisms of Action: CEACAM5 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IMMU-130-02 | P2 |
Terminated |
Colorectal Cancer |
2017-01-03 |
47% |
| IMMU 130-03 | P2 |
Withdrawn |
Colorectal Cancer |
2015-08-01 |
42% |
| IM-T-IMMU-130-01 | P1 |
Completed |
Colorectal Cancer |
2014-12-01 |
42% |